Richard A Larson

List of Publications by Year
in descending order

544 papers	76,842 citations	807 118 h-index	538 265 g-index
566 all docs	566 docs citations	566 times ranked	35948 citing authors

#	Article	IF	Citations
1	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375
2	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	13.9	3,227
3	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine, 2006, 355, 2408-2417.	13.9	3,212
4	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115, 453-474.	0.6	2,963
5	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 4642-4649.	0.8	2,425
6	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
7	Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 2002, 20, 2429-2440.	0.8	1,735
8	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation. New England Journal of Medicine, 2017, 377, 454-464.	13.9	1,628
9	Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 2010, 362, 2251-2259.	13.9	1,497
10	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002, 100, 4325-4336.	0.6	1,444
11	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	0.8	1,188
12	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	0.6	1,184
13	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase. Cancer Cell, 2017, 31, 127-141.	7.7	1,139
14	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.	0.6	1,096
15	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2015, 16, 57-66.	5.1	1,031
16	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2000, 343, 1750-1757.	13.9	939
17	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 2017, 376, 917-927.	13.9	926
18	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. Journal of Clinical Oncology, 2001, 19, 3244-3254.	0.8	837

#	Article	IF	Citations
19	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
20	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 2009, 23, 1054-1061.	3.3	808
21	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	0.6	805
22	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. New England Journal of Medicine, 2019, 381, 1728-1740.	13.9	796
23	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	13.9	706
24	IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 2348-2355.	0.8	699
25	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia, 2016, 30, 1044-1054.	3.3	685
26	Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood, 2003, 102, 43-52.	0.6	630
27	Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2006, 24, 3904-3911.	0.8	618
28	Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 2008, 111, 4022-4028.	0.6	565
29	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003, 101, 6-14.	0.6	549
30	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 2013, 121, 4854-4860.	0.6	546
31	Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology, 2006, 24, 3895-3903.	0.8	541
32	Association of an Inversion of Chromosome 16 with Abnormal Marrow Eosinophils in Acute Myelomonocytic Leukemia. New England Journal of Medicine, 1983, 309, 630-636.	13.9	508
33	Rearrangement of the MLL Gene in Acute Lymphoblastic and Acute Myeloid Leukemias with 11q23 Chromosomal Translocations. New England Journal of Medicine, 1993, 329, 909-914.	13.9	491
34	What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood, 2008, 112, 1646-1654.	0.6	479
35	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology, The, 2011, 12, 841-851.	5.1	444
36	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood, 2010, 116, 3758-3765.	0.6	440

#	Article	IF	Citations
37	MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19971-19976.	3.3	435
38	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 2005, 104, 1442-1452.	2.0	429
39	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine, 2008, 358, 1919-1928.	13.9	427
40	Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15535-15540.	3.3	418
41	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 647-650.	0.6	414
42	Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. American Journal of Medicine, 1984, 76, 827-841.	0.6	410
43	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1â€“2 study. Lancet Oncology, The, 2017, 18, 1061-1075.	5.1	402
44	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 2012, 26, 2197-2203.	3.3	395
45	Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2002, 20, 2441-2452.	0.8	377
46	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 2005, 105, 49-53.	0.6	376
47	Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 2007, 25, 793-798.	0.8	371
48	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 4515-4523.	0.8	363
49	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Blood, 2009, 114, 1126-1126.	0.6	358
50	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood, 2008, 112, 4193-4201.	0.6	357
51	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	0.6	352
52	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, 110, 2309-2315.	0.6	349
53	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116, 3751-3757.	0.6	348
54	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood, 2011, 117, 1141-1145.	0.6	344

#	Article	IF	Citations
55	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 2008, 22, 1200-1206.	3.3	341
56	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002, 100, 1224-1232.	0.6	335
57	Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 5705-5717.	0.8	324
58	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 2007, 25, 799-804.	0.8	320
59	Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 596-604.	0.8	305
60	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 5078-5087.	0.8	294
61	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	7.7	292
62	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood, 2019, 133, 1548-1559.	0.6	292
63	TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2011, 29, 1373-1381.	0.8	291
64	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood, 2007, 109, 5136-5142.	0.6	287
65	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood, 2006, 108, 63-73.	0.6	285
66	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111, 1834-1839.	0.6	284
67	Therapy-Related Myeloid Leukemia. Seminars in Oncology, 2008, 35, 418-429.	0.8	272
68	Prevalence of the Inactivating 609Câ†'T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. Blood, 1999, 94, 803-807.	0.6	264
69	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood, 2011, 118, 6920-6929.	0.6	246
70	Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 742-750.	0.8	244
71	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 2008, 111, 1552-1559.	0.6	243
72	RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures. Journal of Clinical Oncology, 2012, 30, 3109-3118.	0.8	242

#	Article	IF	Citations
73	Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. Journal of Clinical Oncology, 2006, 24, 437-443.	0.8	233
74	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 2014, 123, 1353-1360.	0.6	231
75	Wilmsâ€™ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4595-4602.	0.8	230
76	Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 9234-9242.	0.8	226
77	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood, 2003, 102, 1613-1618.	0.6	222
78	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 2002, 16, 1627-1636.	3.3	217
79	Deletions of Interferon Genes in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1990, 322, 77-82.	13.9	214
80	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica, 2014, 99, 1373-1379.	1.7	213
81	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia, 2013, 27, 107-112.	3.3	212
82	Survival advantage from imatinib compared with the combination interferon-Î± plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 2006, 108, 1478-1484.	0.6	210
83	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 3622-3626.	0.6	201
84	Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study. Journal of Clinical Oncology, 2003, 21, 2138-2146.	0.8	191
85	Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. Journal of Clinical Oncology, 2004, 22, 1087-1094.	0.8	190
86	High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2007, 25, 3337-3343.	0.8	184
87	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	0.8	181
88	Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia. Journal of Clinical Oncology, 2010, 28, 437-444.	0.8	178
89	Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2010, 28, 5257-5264.	0.8	176
90	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood, 2008, 111, 5371-5379.	0.6	174

#	Article	IF	Citations
91	Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood, 2007, 109, 4164-4167.	0.6	173
92	Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 2002, 20, 3878-3884.	0.8	167
93	Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 1172-1181.	0.8	164
94	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021, 35, 440-453.	3.3	159
95	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	0.6	158
96	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 2012, 120, 3898-3905.	0.6	154
97	Blockade of miR-150 Maturation by MLL-Fusion/MYC/LIN-28 Is Required for MLL-Associated Leukemia. Cancer Cell, 2012, 22, 524-535.	7.7	154
98	Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2009, 27, 3198-3204.	0.8	149
99	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology, 2015, 33, 4167-4175.	0.8	149
100	Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology, 2004, 22, 4290-4301.	0.8	145
101	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood, 2012, 119, 2314-2324.	0.6	145
102	THERAPY-RELATED MYELOID LEUKEMIA. Hematology/Oncology Clinics of North America, 1996, 10, 293-320.	0.9	143
103	Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity. Journal of Clinical Oncology, 2005, 23, 3404-3411.	0.8	143
104	Associations between morphology, karyotype, and clinical features in myeloid leukemias. Human Pathology, 1987, 18, 211-225.	1.1	142
105	Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 2001, 19, 3611-3621.	0.8	139
106	Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet, The, 2004, 363, 535-536.	6.3	139
107	Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14925-14930.	3.3	138
108	Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4603-4609.	0.8	138

#	Article	IF	Citations
109	Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2005, 23, 5728-5738.	0.8	134
110	RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nature Communications, 2018, 9, 1163.	5.8	132
111	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. Cancer, 2016, 122, 304-311.	2.0	129
112	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128
113	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	0.6	127
114	Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood, 2005, 105, 3420-3427.	0.6	125
115	Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. American Journal of Medicine, 1988, 84, 233-239.	0.6	124
116	Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805. Clinical Cancer Research, 2005, 11, 4176-4181.	3.2	124
117	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology, 2011, 29, 1349-1355.	0.8	124
118	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.. Blood, 2009, 114, 790-790.	0.6	124
119	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood, 2006, 108, 1677-1683.	0.6	123
120	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation, 2011, 17, 1796-1803.	2.0	123
121	Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 954-964.	2.0	122
122	Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95). Cancer, 2006, 106, 830-838.	2.0	120
123	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2012, 30, 2483-2491.	0.8	120
124	Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2005, 23, 482-493.	0.8	119
125	Rapid Presumptive Diagnosis of Hantavirus Cardiopulmonary Syndrome by Peripheral Blood Smear Review. American Journal of Clinical Pathology, 2001, 116, 665-672.	0.4	115
126	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Advances, 2018, 2, 444-453.	2.5	115

#	Article	IF	Citations
127	Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology, 2008, 26, 4934-4939.	0.8	114
128	P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood, 2010, 116, 1413-1421.	0.6	113
129	miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nature Communications, 2016, 7, 11452.	5.8	113
130	CBFA2(AML1) Translocations With Novel Partner Chromosomes in Myeloid Leukemias: Association With Prior Therapy. Blood, 1998, 92, 2879-2885.	0.6	110
131	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 5660-5669.	0.6	110
132	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review. Biology of Blood and Marrow Transplantation, 2006, 12, 1-30.	2.0	109
133	A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare â€˜poor prognosisâ€™ myeloid malignancies. Leukemia, 2006, 20, 1295-1297.	3.3	109
134	miR-495 is a tumor-suppressor microRNA down-regulated in MLL -rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19397-19402.	3.3	109
135	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer, 2009, 115, 551-560.	2.0	108
136	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 2002, 100, 1224-32.	0.6	105
137	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer, 2013, 119, 90-98.	2.0	104
138	Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes and Cancer, 1990, 2, 147-158.	1.5	103
139	The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: A 12-year study (1970â€“1982). Cancer Genetics and Cytogenetics, 1983, 10, 219-236.	1.0	102
140	Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461. Journal of Clinical Oncology, 2004, 22, 2410-2418.	0.8	101
141	Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3070-3075.	3.3	100
142	Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. Clinical Cancer Research, 2014, 20, 490-498.	3.2	99
143	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	3.3	99
144	Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia, 2010, 24, 1299-1301.	3.3	97

#	Article	IF	Citations
145	miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia â€“rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11511-11516.	3.3	97
146	Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma. Cancer, 2004, 100, 1438-1448.	2.0	96
147	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood, 2004, 103, 4036-4042.	0.6	96
148	Therapy-Related Myelodysplastic Syndrome. American Journal of Clinical Pathology, 2007, 127, 197-205.	0.4	96
149	Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. Journal of Clinical Oncology, 2013, 31, 923-929.	0.8	96
150	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Research, 2005, 29, 1253-1257.	0.4	95
151	Gemtuzumab Ozogamicin: Time to Resurrect?. Journal of Clinical Oncology, 2012, 30, 3921-3923.	0.8	95
152	Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2001, 19, 2482-2492.	0.8	94
153	Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica, 2014, 99, 111-115.	1.7	94
154	Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood, 2009, 113, 5575-5582.	0.6	93
155	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood, 2007, 109, 5164-5167.	0.6	92
156	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2013, 121, 3703-3708.	0.6	91
157	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	0.6	91
158	Transcript Map and Comparative Analysis of the 1.5-Mb Commonly Deleted Segment of Human 5q31 in Malignant Myeloid Diseases with a del(5q). Genomics, 2001, 71, 235-245.	1.3	90
159	MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 2008, 112, 741-749.	0.6	90
160	Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 2004, 104, 3520-3526.	0.6	89
161	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology, 2012, 68, 723-733.	0.8	86
162	Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia, 2012, 26, 959-962.	3.3	84

#	Article	IF	Citations
163	End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood, 2007, 109, 1810-1816.	0.6	83
164	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. Blood, 2014, 124, 796-796.	0.6	83
165	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003.	3.0	82
166	Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 788-792.	0.6	80
167	Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chemico-Biological Interactions, 2010, 184, 50-57.	1.7	80
168	Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Phâ€positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. American Journal of Hematology, 2010, 85, 164-170.	2.0	80
169	Elitekâ„¢â€“rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 2003, 17, 499-514.	3.3	79
170	Etiology and Management of Therapy-Related Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2007, 2007, 453-459.	0.9	79
171	Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia GroupÂB. British Journal of Haematology, 2004, 124, 275-288.	1.2	78
172	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10Â002. British Journal of Haematology, 2014, 165, 102-111.	1.2	78
173	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	0.6	78
174	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
175	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	3.3	76
176	Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1209-1216.	2.0	75
177	Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2007, 40, 1027-1032.	1.3	74
178	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood, 2011, 117, 7007-7013.	0.6	73
179	Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. Best Practice and Research in Clinical Haematology, 2007, 20, 29-37.	0.7	72
180	Therapy-related myeloid neoplasms. Haematologica, 2009, 94, 454-459.	1.7	71

#	Article	IF	Citations
181	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101. Journal of Clinical Oncology, 2010, 28, 4500-4506.	0.8	71
182	The evolving challenge of therapy-related myeloid neoplasms. Best Practice and Research in Clinical Haematology, 2013, 26, 309-317.	0.7	71
183	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood, 2010, 116, 2420-2428.	0.6	70
184	Blinatumomab treatment of older adults with relapsed/refractory Bâ€precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer, 2016, 122, 2178-2185.	2.0	70
185	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia, 2015, 29, 567-575.	3.3	69
186	Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer, 1985, 56, 443-449.	2.0	68
187	A Morphologic and Cytochemical Study of Acute Myelomonocytic Leukemia with Abnormal Marrow Eosinophils Associated with Inv(16)(p13q22). American Journal of Clinical Pathology, 1984, 81, 733-741.	0.4	67
188	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2005, 11, 823-861.	2.0	67
189	Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia. Clinical Cancer Research, 2008, 14, 7095-7101.	3.2	67
190	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia, 2017, 31, 34-39.	3.3	67
191	Overexpression and knockout of miR-126 both promote leukemogenesis. Blood, 2015, 126, 2005-2015.	0.6	65
192	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood, 2012, 120, 249-258.	0.6	64
193	Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemotherapy and Pharmacology, 2002, 50, 37-45.	1.1	62
194	RAS,FLT3, andTP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes and Cancer, 2004, 39, 217-223.	1.5	62
195	Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Advances, 2019, 3, 3488-3498.	2.5	62
196	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer, 2019, 125, 4181-4192.	2.0	61
197	Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine. Cancer, 2003, 97, 1471-1480.	2.0	59
198	Managing CNS disease in adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 3-13.	0.6	59

#	Article	IF	Citations
199	dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations ofTP53. , 1997, 20, 282-291.		58
200	Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013. Journal of Clinical Oncology, 2000, 18, 1301-1308.	0.8	58
201	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 18-36.e6.	2.0	58
202	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. Biology of Blood and Marrow Transplantation, 2015, 21, 559-564.	2.0	58
203	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 2017, 1, 331-340.	2.5	57
204	Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1984, 12, 125-30.	1.1	56
205	Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. Blood, 2003, 102, 7-16.	0.6	56
206	A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology and Oncology, 2012, 5, 71.	6.9	56
207	Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B Studies. Journal of Clinical Oncology, 2013, 31, 440-447.	0.8	56
208	Imatinib 800Âmg daily induces deeper molecular responses than imatinib 400Âmg daily: results of <scp>SWOG</scp> S0325, an intergroup randomized <scp>PHASE II</scp> trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology, 2014, 164, 223-232.	1.2	56
209	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance ofFLT3mutations and complex karyotype. Leukemia and Lymphoma, 2014, 55, 1523-1532.	0.6	55
210	Follow-up of patients with R/R FLT3-mutationâ€“positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood, 2022, 139, 3366-3375.	0.6	55
211	The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Annals of the New York Academy of Sciences, 2014, 1310, 7-31.	1.8	54
212	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2005, 35, 965-970.	1.3	53
213	Management of Acute Lymphoblastic Leukemia in Older Patients. Seminars in Hematology, 2006, 43, 126-133.	1.8	53
214	Acute lymphoblastic leukaemia: diagnosis and classification. Best Practice and Research in Clinical Haematology, 2002, 15, 597-621.	0.7	52
215	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood, 2011, 118, 4188-4198.	0.6	52
216	Treatment-influenced associations of PML-RARÎ± mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood, 2012, 120, 2098-2108.	0.6	52

#	Article	IF	Citations
217	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 4.	6.9	52
218	Metastatic Adenocarcinoma Arising in a Congenital Foregut Cyst of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 64-66.	0.6	52
219	Therapy-related myeloid leukaemia: A model for leukemogenesis in humans. Chemico-Biological Interactions, 2005, 153-154, 187-195.	1.7	51
220	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. JAMA Oncology, 2021, 7, 42.	3.4	51
221	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	3.3	51
222	A Pilot Study of Prophylactic Aerosolized Amphotericin B In Patients at Risk for Prolonged Neutropenia. Leukemia and Lymphoma, 1992, 8, 229-233.	0.6	50
223	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leukemia and Lymphoma, 2009, 50, 1809-1817.	0.6	50
224	Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: Three cases and review of the literature. Mycopathologia, 1988, 101, 105-111.	1.3	49
225	Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood, 2011, 118, 3525-3527.	0.6	49
226	Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (TelintraÂ®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2009, 2, 20.	6.9	48
227	FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 662-667.	0.8	48
228	Eradication of Acute Myeloid Leukemia with FLT3 Ligandâ€“Targeted miR-150 Nanoparticles. Cancer Research, 2016, 76, 4470-4480.	0.4	48
229	A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia, 2003, 17, 323-327.	3.3	46
230	Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research, 2015, 39, 495-500.	0.4	46
231	Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational New Drugs, 2008, 26, 233-239.	1.2	45
232	High rates of durable response are achieved with imatinib after treatment with interferon Â plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica, 2009, 94, 1669-1675.	1.7	45
233	Clinical impact ofABL1kinase domain mutations andIKZF1deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leukemia and Lymphoma, 2016, 57, 2298-2306.	0.6	45
234	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four <scp>CALGB</scp> (alliance) clinical trials. American Journal of Hematology, 2016, 91, 199-204.	2.0	44

#	Article	IF	Citations
235	Treatment of Acute Promyelocytic Leukemia in Adults. Journal of Oncology Practice, 2018, 14, 649-657.	2.5	44
236	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advances, 2020, 4, 696-705.	2.5	44
237	Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies. Journal of Clinical Oncology, 2004, 22, 4816-4822.	0.8	42
238	Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation, 2006, 37, 307-310.	1.3	42
239	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism. Journal of Biological Chemistry, 2010, 285, 32596-32605.	1.6	42
240	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 2014, 99, 1204-1211.	1.7	42
241	Is there a best TKI for chronic phase CML?. Blood, 2015, 126, 2370-2375.	0.6	42
242	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
243	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	3.3	42
244	IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. Blood, 2007, 110, 25-25.	0.6	42
245	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. Blood, 2014, 124, 4541-4541.	0.6	42
246	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 901-901.	0.6	42
247	Refinement of the Smallest Commonly Deleted Segment of Chromosome 20 in Malignant Myeloid Diseases and Development of a PAC-Based Physical and Transcription Map. Genomics, 2000, 67, 28-39.	1.3	41
248	Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosomeâ€”positive acute lymphoblastic leukemia. Leukemia, 2013, 27, 1411-1413.	3.3	41
249	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: longâ€term safety and efficacy. British Journal of Haematology, 2017, 178, 906-913.	1.2	41
250	Adult de novo acute myeloid leukemia with t(6;11)(q27;q23). Cancer, 2004, 101, 1420-1427.	2.0	40
251	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia and Lymphoma, 2010, 51, 2240-2249.	0.6	40
252	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 913-921.	2.0	40

#	Article	IF	Citations
253	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clinical Cancer Research, 2002, 8, 2812-9.	3.2	40
254	Acute leukemia in adults: recent developments in diagnosis and treatment. Ca-A Cancer Journal for Clinicians, 1994, 44, 326-352.	157.7	39
255	inv(16)/t(16;16) acute myeloid leukemia with nonâ€“type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood, 2013, 121, 385-391.	0.6	39
256	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Annals of Hematology, 2015, 94, 249-257.	0.8	39
257	Randomized trial of 10 days of decitabine Â± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances, 2018, 2, 3608-3617.	2.5	39
258	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology, 2014, 165, 497-503.	1.2	38
259	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). Journal of Geriatric Oncology, 2020, 11, 107-113.	0.5	38
260	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer, 2013, 119, 4170-4179.	2.0	37
261	Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia, 2015, 29, 2113-2116.	3.3	37
262	High-energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: Treatment technique and related complications. International Journal of Radiation Oncology Biology Physics, 1998, 40, 391-396.	0.4	36
263	Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics Journal, 2017, 17, 274-279.	0.9	35
264	Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia, 2003, 17, 691-699.	3.3	34
265	The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leukemia and Lymphoma, 2013, 54, 252-254.	0.6	34
266	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	2.5	34
267	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	2.5	34
268	Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: A review of three consecutive trials of the treatment of poor prognosis patients. Leukemia Research, 1991, 15, 773-780.	0.4	33
269	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood, 2010, 116, 5650-5659.	0.6	33
270	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Advances, 2018, 2, 1522-1531.	2.5	33

#	Article	IF	Citations
271	Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1030-1035.	3.3	32
272	Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica, 2014, 99, 308-313.	1.7	32
273	Three New Drugs for Acute Lymphoblastic Leukemia: Nelarabine, Clofarabine, and Forodesine. Seminars in Oncology, 2007, 34, S13-S20.	0.8	31
274	Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemiaâ€"Results of a Phase I Dose-Escalation Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 443-449.	0.2	31
275	Acute Lymphoblastic Leukemia: Older Patients and Newer Drugs. Hematology American Society of Hematology Education Program, 2005, 2005, 131-136.	0.9	30
276	A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemotherapy and Pharmacology, 2009, 63, 859-864.	1.1	30
277	Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplantation, 2009, 44, 353-359.	1.3	30
278	Cytogenetics, Not Just Previous Therapy, Determines the Course of Therapy-Related Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 2300-2302.	0.8	30
279	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	1.7	30
280	Reimmunization after allogeneic bone marrow transplantation. American Journal of Medicine, 1995, 98, 389-398.	0.6	29
281	PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER â€œGOOD RISKâ€•ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011032.	0.5	29
282	The spectrum of somatic mutations in highâ€risk acute myeloid leukaemia with â€7/del(7q). British Journal of Haematology, 2014, 166, 550-556.	1.2	29
283	Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.. Blood, 2008, 112, 3238-3238.	0.6	29
284	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Advances, 2021, 5, 504-512.	2.5	28
285	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	3.3	28
286	c-myc and c-myb expression in acute myelogenous leukemia. Leukemia Research, 1992, 16, 1003-1011.	0.4	27
287	High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leukemia Research, 2011, 35, 329-333.	0.4	27
288	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemotherapy and Pharmacology, 2014, 74, 927-938.	1.1	27

#	Article	IF	Citations
289	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood, 2021, 138, 639-639.	0.6	27
290	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood, 2023, 141, 156-167.	0.6	27
291	High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection. Biomedical Applications, 1987, 420, 81-88.	1.7	26
292	Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemotherapy and Pharmacology, 2006, 57, 199-206.	1.1	26
293	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. European Journal of Cancer, 2021, 157, 428-440.	1.3	26
294	Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study. American Journal of Hematology, 1993, 43, 286-290.	2.0	25
295	Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia and Lymphoma, 2009, 50, 1589-1596.	0.6	25
296	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2012, 70, 345-350.	1.1	25
297	Recombinant interleukinâ€2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808. Cancer, 2014, 120, 1010-1017.	2.0	25
298	Acute Myelomonocytic Leukemia with Abnormal Eosinophils Presenting as an Ovarian Mass: A Report of Two Cases and a Review of the Literature. Gynecologic Oncology, 1995, 56, 307-311.	0.6	24
299	Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia, 2011, 25, 800-807.	3.3	24
300	WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Experimental Hematology and Oncology, 2018, 7, 1.	2.0	24
301	Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 536-536.	0.6	24
302	Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	2.5	24
303	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia Research, 2003, 27, 1091-1096.	0.4	23
304	Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia. Clinical Cancer Research, 2005, 11, 8089-8096.	3.2	23
305	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia, 2013, 27, 907-913.	3.3	23
306	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leukemia and Lymphoma, 2013, 54, 1242-1249.	0.6	23

#	Article	IF	Citations
307	Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. British Journal of Haematology, 1991, 79, 33-39.	1.2	22
308	The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure. British Journal of Haematology, 1991, 79, 390-397.	1.2	22
309	Phase I Trial of a Genetically Engineered Interleukin-2 Fusion Toxin (DAB₄₈₆IL-2) as a 6 Hour Intravenous Infusion in Patients with Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 257-262.	0.6	22
310	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017, 102, 519-528.	1.7	22
311	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer Journal, 2021, 11, 39.	2.8	22
312	Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. Blood, 2019, 134, 2924-2924.	0.6	22
313	Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.. Blood, 2007, 110, 157-157.	0.6	22
314	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. Seminars in Oncology, 2011, 38, 215-224.	0.8	21
315	Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?. Seminars in Oncology, 2011, 38, 196-214.	0.8	21
316	A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Investigational New Drugs, 2013, 31, 1311-1320.	1.2	21
317	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leukemia Research, 2014, 38, 329-333.	0.4	21
318	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Experimental Hematology and Oncology, 2019, 8, 1.	2.0	21
319	Long-term follow-up of cancer and leukemia group B studies in acute myeloid leukemia. Cancer, 1997, 80, 2210-2214.	2.0	20
320	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica, 2011, 96, 1488-1495.	1.7	20
321	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia and Lymphoma, 2012, 53, 445-450.	0.6	20
322	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1065-1072.	2.0	20
323	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2127-2133.	0.6	20
324	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia, 2021, 35, 2220-2231.	3.3	20

#	Article	IF	Citations
325	HYPERSENSITIVITY REACTION TO HIGH-DOSE CYTARABINE. British Journal of Haematology, 1989, 73, 274-275.	1.2	19
326	ACUTE MYELOID LEUKAEMIA FOLLOWING INTERFERON-ALFA TREATMENT OF HAIRY CELL LEUKAEMIA. British Journal of Haematology, 1993, 83, 519-520.	1.2	19
327	The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia, 2012, 26, 1713-1717.	3.3	19
328	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.. Blood, 2005, 106, 407-407.	0.6	19
329	Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301.. Blood, 2006, 108, 797-797.	0.6	19
330	New high-performance liquid chromatographic assay for plasma doxorubicin. Biomedical Applications, 1985, 337, 194-200.	1.7	18
331	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 16-17.	2.0	18
332	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplantation, 2013, 48, 1437-1443.	1.3	18
333	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
334	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	0.6	18
335	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood, 2008, 112, 2809-2809.	0.6	18
336	Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy. European Journal of Cancer & Clinical Oncology, 1985, 21, 563-571.	0.9	17
337	Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma, 2003, 44, 39-48.	0.6	17
338	Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: Characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. Leukemia Research, 2014, 38, 1091-1096.	0.4	17
339	miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Brutonâ€™s tyrosine kinase inhibition with Ibrutinib. Leukemia, 2015, 29, 1210-1213.	3.3	17
340	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	0.6	17
341	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
342	Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings. Cancer, 1982, 49, 2222-2225.	2.0	16

#	Article	IF	Citations
343	The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study. British Journal of Haematology, 1992, 82, 337-346.	1.2	16
344	Listeriosis after 2-Chlorodeoxyadenosine Treatment. New England Journal of Medicine, 1993, 328, 813-814.	13.9	16
345	t(1;3)(p36;p21) is a recurring therapy-related translocation. Genes Chromosomes and Cancer, 2002, 34, 186-192.	1.5	16
346	Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia and Lymphoma, 2007, 48, 1799-1805.	0.6	16
347	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 995-1006.	0.6	16
348	Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy, 2012, 14, 707-715.	0.3	16
349	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leukemia and Lymphoma, 2012, 53, 1743-1748.	0.6	16
350	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances, 2018, 2, 1705-1718.	2.5	16
351	Preliminary Experience with a New Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2001, 41, 297-307.	0.6	15
352	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. International Journal of Oncology, 2002, 21, 1041.	1.4	15
353	Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematologica, 2016, 136, 210-218.	0.7	15
354	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer, 2018, 18, 359.	1.1	15
355	Imatinib is still recommended for frontline therapy for CML. Blood Advances, 2018, 2, 3648-3652.	2.5	15
356	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	2.5	15
357	Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing) Tj ETQq1 1 0.784314 rgBT /Ove Acute Lymphoblastic Leukemia (B-ALL). Blood, 2020, 136, 7-8.	0.6	15
358	Polymorphisms in the MLL breakpoint cluster region (BCR). Human Genetics, 2003, 113, 80-91.	1.8	14
359	Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatric Blood and Cancer, 2019, 66, e27542.	0.8	14
360	Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.. Blood, 2007, 110, 2815-2815.	0.6	14

#	Article	IF	Citations
361	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230.	0.6	14
362	der(5)t(5;7)(q11.2;p11.2): A new recurring abnormality in malignant myeloid disorders. Cancer Genetics and Cytogenetics, 1989, 37, 1-8.	1.0	13
363	Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. American Journal of Hematology, 1993, 42, 147-157.	2.0	13
364	Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Current Opinion in Hematology, 2003, 10, 284-289.	1.2	13
365	Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 2711-2718.	0.9	13
366	Micro-RNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia. Chemico-Biological Interactions, 2010, 184, 21-25.	1.7	13
367	GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011019.	0.5	13
368	PepsiÂ® or CokeÂ®? Influence of acid on dasatinib absorption. Journal of Oncology Pharmacy Practice, 2018, 24, 156-158.	0.5	13
369	Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. International Journal of Oncology, 2002, 21, 1041-51.	1.4	13
370	Inhibition of DNA synthesis by cytosine arabinoside: Relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. European Journal of Cancer & Clinical Oncology, 1984, 20, 1061-1068.	0.9	12
371	Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1989, 216, 119-126.	0.4	12
372	Myelodysplasia: When to treat and how. Best Practice and Research in Clinical Haematology, 2006, 19, 293-300.	0.7	12
373	A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational New Drugs, 2008, 26, 331-338.	1.2	12
374	Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia â€“ Cancer and leukemia group B study 10107. Leukemia and Lymphoma, 2008, 49, 1274-1278.	0.6	12
375	Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leukemia and Lymphoma, 2009, 50, 85-91.	0.6	12
376	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncology Practice, 2020, 16, e464-e475.	1.4	12
377	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 2021, 35, 2854-2861.	3.3	12
378	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. Blood, 2010, 116, 2291-2291.	0.6	12

#	Article	IF	Citations
379	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. Blood, 2012, 120, 1686-1686.	0.6	12
380	Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?. Leukemia, 2003, 17, 488-491.	3.3	11
381	Fifty Years of Clinical Research by the Leukemia Committee of the Cancer and Leukemia Group B. Clinical Cancer Research, 2006, 12, 3556s-3563s.	3.2	11
382	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia and Lymphoma, 2008, 49, 531-537.	0.6	11
383	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq1 1 0.784314 rgBT /Over	2.5	11
384	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplantation, 2020, 55, 1161-1168.	1.3	11
385	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	0.6	11
386	Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. American Journal of Hematology, 1993, 42, 359-366.	2.0	10
387	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology, 2006, 28, 1099.	1.4	10
388	Allogeneic Hematopoietic Cell Transplantation Is Not Recommended for all Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2009, 15, 11-16.	2.0	10
389	Longâ€term outcomes for newlyâ€diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of <scp>CALGB</scp> (Alliance) 10301, a multicentre phase <scp>II</scp> study. British Journal of Haematology, 2015, 171, 373-377.	1.2	10
390	The Histone Deacetylase Inhibitor Depsipeptide Has Differential Activity in Specific Cytogenetic Subsets of Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 264-264.	0.6	10
391	Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology, 2006, 28, 1099-103.	1.4	10
392	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Advances, 2022, 6, 4085-4092.	2.5	10
393	Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Cancer, 1990, 65, 2619-2623.	2.0	9
394	Current Practices in the Management of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 48-54.	0.2	9
395	Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. Leukemia and Lymphoma, 2013, 54, 2654-2659.	0.6	9
396	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leukemia and Lymphoma, 2015, 56, 3031-3037.	0.6	9

#	Article	IF	Citations
397	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia and Lymphoma, 2016, 57, 1807-1813.	0.6	9
398	Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection. Journal of Clinical Oncology, 2016, 34, e46-e48.	0.8	9
399	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	2.5	9
400	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 2022, 114, 160-164.	3.0	9
401	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances, 2021, 5, 4691-4700.	2.5	9
402	Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.. Blood, 2006, 108, 429-429.	0.6	9
403	Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).. Blood, 2007, 110, 756-756.	0.6	9
404	Prevalence of the Inactivating 609Câ†'T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. Blood, 1999, 94, 803-807.	0.6	9
405	Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. Translational Pediatrics, 2012, 1, 120-2.	0.5	9
406	Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2021, 138, 1746-1746.	0.6	9
407	Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Advances, 2022, 6, 3812-3820.	2.5	9
408	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718.	0.8	9
409	Chromosome Changes in Hematologic Malignancies. Ca-A Cancer Journal for Clinicians, 1981, 31, 222-238.	157.7	8
410	Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplantation, 2008, 42, S18-S24.	1.3	8
411	A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs, 2015, 33, 371-379.	1.2	8
412	Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. Journal of Geriatric Oncology, 2020, 11, 1199-1209.	0.5	8
413	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. Blood, 2011, 118, 289-289.	0.6	8
414	High early death rates, treatment resistance, and short survival ofÂBlack adolescents and young adults with AML. Blood Advances, 2022, 6, 5570-5581.	2.5	8

#	Article	IF	Citations
415	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-Î±: A Cancer and Leukemia Group B study. International Journal of Oncology, 2004, 25, 143.	1.4	7
416	Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leukemia Research, 2004, 28, 537-540.	0.4	7
417	Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: <scp>CALGB</scp> 10105 (<scp>A</scp>lliance). British Journal of Clinical Pharmacology, 2014, 78, 1005-1013.	1.1	7
418	Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder. Blood, 2010, 116, 2709-2709.	0.6	7
419	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. Blood, 2011, 118, 258-258.	0.6	7
420	Poor prognosis acute myelogenous leukemia: 1 â€“ response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leukemia Research, 2000, 24, 671-680.	0.4	6
421	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.	0.6	6
422	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan. Cancer, 2009, 115, 84-93.	2.0	6
423	Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Current Opinion in Oncology, 2009, 21, 601-608.	1.1	6
424	Amelanocytic Anhidrotic Alopecia Areata-like Phenotype After Allogeneic Hematopoietic Cell Transplant. Archives of Dermatology, 2012, 148, 931.	1.7	6
425	Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?. Best Practice and Research in Clinical Haematology, 2019, 32, 101102.	0.7	6
426	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	2.5	6
427	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). Blood, 2018, 132, 2800-2800.	0.6	6
428	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. Blood, 2014, 124, 738-738.	0.6	6
429	utility of ultrasound in the diagnosis of wandering abdominal viscera. Journal of Clinical Ultrasound, 1985, 13, 275-277.	0.4	5
430	A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemotherapy and Pharmacology, 2004, 54, 553-561.	1.1	5
431	Chronic Lymphocytic Leukemia Masquerading as Uveitis. Retina, 2007, 27, 1311-1312.	1.0	5
432	Is there a best TKI for chronic phase CML?. Hematology American Society of Hematology Education Program, 2015, 2015, 250-256.	0.9	5

#	Article	IF	Citations
433	Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2020, 55, 2204-2206.	1.3	5
434	Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer, 1997, 80, 2210-4.	2.0	5
435	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. Blood, 2019, 134, 261-261.	0.6	5
436	A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.. Blood, 2004, 104, 873-873.	0.6	5
437	Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. Blood, 2005, 106, 1833-1833.	0.6	5
438	Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 1848-1848.	0.6	5
439	Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 2772-2772.	0.6	5
440	Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase. Blood, 2016, 128, 2706-2706.	0.6	5
441	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances, 2022, 6, 3433-3439.	2.5	5
442	Relapse of Hodgkin's Disease After 14 Years of Complete Remission. Leukemia and Lymphoma, 1990, 3, 223-226.	0.6	4
443	Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. Leukemia Research, 1991, 15, 51-57.	0.4	4
444	Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opinion on Pharmacotherapy, 2006, 7, 1791-1799.	0.9	4
445	Therapy-related myeloid sarcoma with anNPM1mutation. Leukemia and Lymphoma, 2010, 51, 2130-2131.	0.6	4
446	CML: live long and prosper. Blood, 2011, 118, 4499-4500.	0.6	4
447	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 629-638.	0.6	4
448	Patientsâ€™ perspectives on the definition of cure in chronic myeloid leukemia. Leukemia Research, 2019, 80, 40-42.	0.4	4
449	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem, 2021, 2, 413-420.	0.4	4
450	Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B. , 2008, , 137-144.		4

#	Article	IF	Citations
451	Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).. Blood, 2005, 106, 165-165.	0.6	4
452	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood, 2012, 120, 44-44.	0.6	4
453	Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study. Blood, 2014, 124, 1093-1093.	0.6	4
454	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). Blood, 2018, 132, 1386-1386.	0.6	4
455	High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia. European Journal of Cancer & Clinical Oncology, 1985, 21, 1261-1263.	0.9	3
456	A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 1988, 35, 143-150.	1.0	3
457	Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 829-832.	0.6	3
458	Geriatric Assessment (GA) to Predict Survival in Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2014, 20, S39-S40.	2.0	3
459	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). Blood, 2018, 132, 435-435.	0.6	3
460	Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors. Blood, 2019, 134, 4176-4176.	0.6	3
461	Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication. Blood, 2019, 134, 475-475.	0.6	3
462	Treatment Failure Is Strongly Predicted by P-Glycoprotein (Pgp) Function but Not by Multidrug Resistance Protein (MRP-1), Breast Cancer Resistance Protein (BCRP) or Lung Resistance Protein (LRP) in Acute Myeloid Leukemia (AML) Patients 60 Years and Older Receiving Intensive Chemotherapy (CALGB) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	3
463	Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients â‰¥ 65 Years of Age.. Blood, 2005, 106, 2524-2524.	0.6	3
464	CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.. Blood, 2006, 108, 2293-2293.	0.6	3
465	Abl Kinase Domain Mutations Leading to Relapse of Ph+ Acute Lymphoblastic Leukemia (ALL) Occur Commonly and Can Be Detected At Initial Diagnosis: Molecular Results From CALGB 10001. Blood, 2011, 118, 2541-2541.	0.6	3
466	Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2518-2518.	0.6	3
467	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. Blood, 2019, 134, 705-705.	0.6	3
468	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leukemia Research, 2021, 111, 106736.	0.4	3

#	Article	IF	Citations
469	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Advances, 0, , .	2.5	3
470	Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1986, 18, 257-60.	1.1	2
471	Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU. Investigational New Drugs, 1988, 6, 121-124.	1.2	2
472	Effects of rhGM-CSF on Myeloid Clonogenic Cells in Acute Myelogenous Leukemia Patients. Leukemia and Lymphoma, 1993, 10, 183-186.	0.6	2
473	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. Blood, 2003, 102, 2309-2310.	0.6	2
474	Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. Leukemia and Lymphoma, 2009, 50, 868-870.	0.6	2
475	Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Reports in Hematology, 2013, 2013, 1-3.	0.3	2
476	Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 1956-1956.	0.6	2
477	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. Blood, 2020, 136, 41-42.	0.6	2
478	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. Blood, 2004, 104, 918-918.	0.6	2
479	Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [â‰¥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.. Blood, 2009, 114, 1579-1579.	0.6	2
480	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Blood, 2011, 118, 114-114.	0.6	2
481	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. Blood, 2012, 120, 676-676.	0.6	2
482	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. Blood, 2015, 126, 3784-3784.	0.6	2
483	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. Blood, 2014, 124, 2509-2509.	0.6	2
484	ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Blood, 2018, 132, 1739-1739.	0.6	2
485	High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance). Blood, 2021, 138, 221-221.	0.6	2
486	Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B. Cellular Immunology, 1983, 81, 357-372.	1.4	1

#	Article	IF	Citations
487	Neurocysticercosis Coincident with Acute Myeloid Leukemia: A Case Report. Leukemia and Lymphoma, 1991, 4, 145-148.	0.6	1
488	Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemotherapy and Pharmacology, 1995, 36, 204-210.	1.1	1
489	Therapy-related myeloid leukemia: stochastic or idiosyncratic?. Blood, 2004, 104, 602-603.	0.6	1
490	Positron Emission Tomographyâ€“Computed Tomography Imaging of a Patient With Several Myeloid Sarcomas With FLT3-ITD and NPM1 Mutations. Journal of Clinical Oncology, 2016, 34, e123-e125.	0.8	1
491	Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. Hematologic Malignancies, 2021, , 93-104.	0.2	1
492	Economics influences therapy decisions in chronic myeloid leukaemia: should it?. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3693-3698.	1.2	1
493	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). Blood, 2018, 132, 1534-1534.	0.6	1
494	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	0.6	1
495	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	0.6	1
496	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	0.6	1
497	Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)â€“An International Study. Blood, 2011, 118, 2521-2521.	0.6	1
498	Therapy-Related Myeloid Neoplasms (t-MN) in 71 Patients Following Radiation Therapy (RT) Only,. Blood, 2011, 118, 3522-3522.	0.6	1
499	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 3535-3535.	0.6	1
500	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548.	0.6	1
501	Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia. Blood, 2016, 128, 214-214.	0.6	1
502	WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia. Blood, 2016, 128, 3984-3984.	0.6	1
503	Genomic Rearrangements Associated with -5/del(5q) and -7/del(7q) in Myeloid Leukemias.. Blood, 2007, 110, 1813-1813.	0.6	1
504	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. Blood, 2011, 118, 830-830.	0.6	1

#	Article	IF	Citations
505	Blockade of Mir-150 Maturation by MLL-Fusion/MYC/Lin-28 Is Required for MLL-Associated Leukemia. Blood, 2012, 120, 3499-3499.	0.6	1
506	Overexpression and Knockout of Mir-126 Both Promote Leukemogenesis through Targeting Distinct Gene Signaling. Blood, 2015, 126, 3667-3667.	0.6	1
507	Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality. Blood, 2016, 128, 5844-5844.	0.6	1
508	Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?. Pediatric Blood and Cancer, 2022, , e29613.	0.8	1
509	The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: The role of granulocytes as a helper population. Journal of Allergy and Clinical Immunology, 1984, 74, 280-290.	1.5	0
510	Myeloid Leukemia After Cytotoxic Therapy and Other Hematotoxins. Hematology, 1998, 3, 397-400.	0.7	0
511	Rates of cholesterol biosynthesis are related to early differentiation in acute nonâ€lymphocytic leukaemia cells. British Journal of Haematology, 1983, 54, 459-466.	1.2	0
512	Author reply to Fujimi et al. European Journal of Clinical Pharmacology, 2012, 68, 1573-1574.	0.8	0
513	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. Hematologic Malignancies, 2016, , 231-255.	0.2	0
514	Allo-HSCT in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Blinatumomab vs Standard-of-Care Chemotherapy From a Randomized Phase 3 Study. Biology of Blood and Marrow Transplantation, 2018, 24, S105-S106.	2.0	0
515	Therapy-Related Acute Promyelocytic Leukemia. , 2018, , 231-242.		0
516	Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.. Blood, 2004, 104, 3485-3485.	0.6	0
517	Is Family History of Breast Cancer Associated with Therapy-Related Myelodysplastic Syndrome and Therapy-Related Leukemia? .. Blood, 2004, 104, 2018-2018.	0.6	0
518	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. Blood, 2005, 106, 1818-1818.	0.6	0
519	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1952-1952.	0.6	0
520	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	0.6	0
521	MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.. Blood, 2007, 110, 3181-3181.	0.6	0
522	Treatment of Acute Lymphoblastic Leukemia in Middle-Age and Older Adults. , 2011, , 115-126.		0

#	Article	IF	Citations
523	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. Blood, 2011, 118, 1948-1948.	0.6	0
524	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. Blood, 2011, 118, 1791-1791.	0.6	0
525	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. Blood, 2011, 118, 236-236.	0.6	0
526	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	0.6	0
527	MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2011, 118, 1462-1462.	0.6	0
528	Methyl Transferase Activity in Secondary Leukemia. , 1990, 53, 277-289.		0
529	Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2463-2463.	0.6	0
530	Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric Assessment (GA). Blood, 2014, 124, 2464-2464.	0.6	0
531	Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3777-3777.	0.6	0
532	Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.. Journal of Clinical Oncology, 2016, 34, e18537-e18537.	0.8	0
533	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	0.6	0
534	Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. Blood, 2018, 132, 5843-5843.	0.6	0
535	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	0.6	0
536	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	0.6	0
537	Acute Lymphoblastic Leukemia: Clinical Presentation, Diagnosis, and Classification. Hematologic Malignancies, 2021, , 157-167.	0.2	0
538	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. Blood, 2021, 138, 337-337.	0.6	0
539	Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance). Blood, 2021, 138, 226-226.	0.6	0
540	White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance). Blood, 2021, 138, 3369-3369.	0.6	0

#	Article	IF	Citations
541	Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only. Blood, 2020, 136, 25-26.	0.6	0
542	Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT). Blood, 2020, 136, 39-40.	0.6	0
543	Acute Myeloid Leukemia in Adults: Remission Induction Therapy. , 0, , 268-277.		0
544	Acute Myeloid Leukemia in Adults: Postremission Therapy. , 0, , 278-286.		0